A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection

• Drug: Tigecycline
  
  every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
• Drug: Imipenem/cilastatin
  
  every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.

• Experimental: Group A
  
  Intervention: Drug: Tigecycline
• Active Comparator: Group B
  
  Intervention: Drug: Imipenem/cilastatin

Inclusion Criteria:

• Hospitalized male or female subjects, at least 18 year of age.
• Complicated intra-abdominal infection is present at most under two weeks duration.
• Minimal clinical criteria at the time of intra-abdominal infection diagnosis or highly suspected intra-abdominal infection.

Exclusion Criteria:

• Anticipated length of antibiotic therapy less than 5 days or the likelihood that the subject will not complete the course of treatment.
• Intra-abdominal infection known to be caused by 1 or more bacterial pathogens not susceptible to both of the study drugs.
• Had accepted non-study antibiotics more than 24 hr within 72 hrs before enrollment except for subjects declared prior failures.